* Maravai LifeSciences Holdings Inc MRVI.OQ reported
quarterly
breakeven results per share for the quarter ended in January,
identical to the same quarter last year. The mean expectation
of twelve analysts for the quarter was for breakeven results per
share. Wall Street expected results to range from -1 cents to 2
cents per share.
* Revenue rose 6.5% to $73.40 million from a year ago;
analysts
expected $71.63 million.
* Maravai LifeSciences Holdings Inc's reported EPS for the
quarter
was a loss of 6 cents.
* The company reported a quarterly loss of $7.59 million.
* Maravai LifeSciences Holdings Inc shares had risen
by 27.0% this
quarter and gained 38.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 127.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Maravai
LifeSciences Holdings Inc is $10.00
This summary was machine generated from LSEG data August 7 at
10:44 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 0.00 0.00 Met
Mar. 31 2024 -0.03 -0.02 Beat
Dec. 31 2023 -0.01 0.01 Beat
Sep. 30 2023 0.01 -0.01 Missed